IMUNA PHARM

What IMUNA PHARM does

IMUNA PHARM, a.s. is a privately held Slovak pharmaceutical manufacturer headquartered in Šarišské Michaľany, operating continuously in some form since 1953 (privatized as a joint-stock company in 2002) with a workforce of 51-100 employees. The company produces a diversified portfolio spanning disinfection solutions, sterile infusion and irrigation solutions, immunopreparations (IMMODIN, ALTEANA), blood derivatives (in partnership with Instituto Grifols, making it the only Slovak provider of blood derivatives from Slovak plasma), activated charcoal digestive products, dialysis concentrates, cell implants (Improderm, Chondroautocell, Epiderm), and vaccines. Manufacturing is supported by modern Form-Fill-Seal (FFS) automated lines producing PP flexible bags from 50 to 5,000 ml at up to 4,000 units per hour, alongside cleanroom facilities classified to D, C, and B/A standards, and a dedicated tissue establishment for cell engineering.

The business operates two complementary revenue streams. First, it sells proprietary branded pharmaceutical and disinfectant products directly to Slovak healthcare providers, hospitals, pharmacies, and consumers via an e-commerce storefront (obchod.imuna.sk), with disinfectant products distributed via courier and personal pickup. Second, it provides full-cycle contract manufacturing services to multinational pharmaceutical companies covering procurement, development, validation, processing, packaging, labeling, quality control, releasing, and warehousing — particularly for single and multi-chamber flexible bag solutions. Pricing for OTC disinfectants is publicly listed, while B2B and contract manufacturing pricing is quote-based.

IMUNA PHARM is heavily certified under EU regulatory frameworks — holding GMP certificates for sterile and non-sterile products, GDP for distribution, ISO 9001:2015, ISO 13485:2016, CE Mark under 93/42/EEC, and a veterinary GMP — enabling access to demanding international pharmaceutical markets. The company has been an active recipient of EU structural and R&D grant funding, securing seven grants between 2010 and 2015 that supported modernization of IMMODIN production, infusion manufacturing, and dialysis technology, as well as vaccine R&D with Slovak Academy of Sciences partners and the Probiotech consortium. Headquartered at a single site in eastern Slovakia, the company is privately held with no disclosed parent, equity investors, or public shareholders.

Name

IMUNA PHARM

Legal name

IMUNA PHARM, a.s.

Website

https://imuna.sk

Company type

Private

Founded year

1953

Operating status

Operating

Headcount range

51–100 employees

Short description

IMUNA PHARM is a privately held Slovak pharmaceutical manufacturer (founded 1953, privatized 2002) producing disinfectants, infusion and irrigation solutions, immunopreparations, blood derivatives, cell implants, and vaccines, while also offering contract manufacturing for multinational pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Surgical Appliance and Supplies Manufacturing (339113), Soap, Cleaning Compound, and Toilet Preparation Manufacturing (3256)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840)

akta.pro primary industry

Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers) (IMALAIAB)

akta.pro secondary industries

Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical manufacturing
• Infusion solutions
• Disinfectant products
• Contract manufacturing
• Cell implants

Headquarters

HQ city

Ostrovany

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Own Branded Pharmaceutical Products: Sale of proprietary pharmaceutical products including immunopreparations (IMMODIN, ALTEANA), disinfectants (Dezinfectol IMUNA, Dezinfectol SURFACE, AntiMicrol GEL), infusion solutions, irrigation solutions, blood derivatives, cell implants, and Carbo digestive products. Both prescription and OTC products.
2. Contract Manufacturing Services: Full-service pharmaceutical contract manufacturing for multinational companies. Services include procurement of substances, development, validations, processing design/verification/control, packaging/labeling, laboratory testing, quality assurance, releasing, and warehousing. Manufacturing of single and multi-chamber bags from 100ml to 5000ml.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

IMUNA PHARM is a Slovak pharmaceutical manufacturer producing and distributing proprietary branded products including disinfectants, infusion and irrigation solutions, immunopreparations (IMMODIN, ALTEANA), blood derivatives, digestive medications (Carbo line), cell implants, and dialysis concentrates. The company also provides full-cycle contract manufacturing services for multinational pharmaceutical companies, covering single and multi-chamber PP flexible bag production from 100ml to 5000ml, with substance procurement, validation, processing, quality control, packaging, labeling, and release.

Product overview

IMUNA PHARM is a Slovak pharmaceutical company offering a diversified portfolio of pharmaceutical products and contract manufacturing services. The product portfolio spans multiple therapeutic categories: disinfection solutions (Dezinfectol IMUNA, Dezinfectol SURFACE, AntiMicrol GEL) for hand and surface sanitation; infusion and irrigation solutions (AQUA PRO INJEKCIONE, Sodium chloride, glucose solutions, mannitol, Ringer, IRRISOL products) for parenteral administration; immunopreparations (IMMODIN immunomodulator, ALTEANA anti-tetanus vaccine); digestive medications (CARBOTOX, CARBOSORB, CARBOCIT activated charcoal products); blood derivatives in cooperation with Grifols; and cell implant therapies (Improderm, Chondroautocell, Epiderm). The company also provides contract manufacturing services for pharmaceutical solutions in flexible bags and operates in 5 basic technological areas including vaccine production, blood derivatives, infusions, diagnostics, and biotechnology products.

Differentiator

Problem solved

Functional benefit

Brands

• Dezinfectol IMUNA: Disinfection solution for rapid hand disinfection with virucidal and bactericidal effect, based on WHO recommendations
• Dezinfectol SURFACE
• AntiMicrol GEL
• IMMODIN
• ALTEANA
• CARBOTOX
• CARBOSORB
• CARBOCIT
• IRRISOL
• INFUSIO
• AQUA PRO INJEKCIONE IMUNA
• Improderm
• Chondroautocell
• Epiderm

Products and services

• Dezinfectol IMUNA Hand disinfectant solution for rapid disinfection of human skin with virucidal and bactericidal effect, based on WHO-recommended formulation. Targeted at consumers and healthcare professionals.
• Dezinfectol SURFACE Surface and instrument disinfectant solution with virucidal and bactericidal effect, based on BAuA-recommended formulation. For consumer and institutional surface sanitation.
• AntiMicrol GEL Alcohol-based hand disinfectant gel with bactericidal and virucidal effect, suitable for consumers and healthcare settings.
• Infusion solutions (INFUSIO line) Sterile infusion solutions including AQUA PRO INJEKCIONE, Sodium chloride 0.9%, glucose (5%-40%), mannitol (10%, 20%), Ringer, and potassium chloride concentrate in volumes from 100ml to 1000ml. For healthcare providers and hospitals.
• Irrigation solutions (IRRISOL) Sterile wound irrigation solutions including Sodium chloride 0.9%, Ringer IRRISOL, and AQUA IRRISOL in 1000ml to 5000ml volumes. For healthcare providers for wound care.
• Blood derivatives (KD) Blood plasma derivatives produced in cooperation with Grifols, processed from Slovak plasma and returned to the Slovak market as medical substances. IMUNA PHARM is the only company in Slovakia offering blood derivatives from Slovak plasma.
• IMMODIN Lyophilized human leucocyte-derived dialysate immunomodulator (ATC code: L03AX) containing biologically active substances that normalize cell-mediated immunity, indicated for cellular immune disorders.
• ALTEANA Anti-tetanus vaccine (ATC code: J07AM01) prepared from inactivated tetanus toxin adsorbed on aluminum hydroxide for primary and booster vaccination against tetanus, inducing specific antibody production after intramuscular application.
• CARBOTOX Activated charcoal tablets (ATC code: A07BA51) containing Carbo activatus and Natrii thiosulfas for treatment of acute diarrhoea, food poisoning, and irritable bowel syndrome in adults, adolescents, and children from 3 years.
• CARBOSORB Oral powder and tablets containing activated charcoal (Carbo activatus) for treatment of acute diarrhoea, viral and bacterial intestinal infections, irritable bowel syndrome, and acute intoxications in adults and children from 3 years.
• CARBOCIT Tablets containing activated charcoal, Bismuth subgallas, and Citric acid for treatment of acute diarrhoea with local disinfectant and astringent effect in the digestive tract.
• Cell implants Tissue establishment products for cell engineering including Improderm (cultured autologous fibroblasts), Chondroautocell (cultured autologous chondrocytes), and Epiderm (cultured allogeneic skin cells on carrier) for musculoskeletal, cardiovascular, and skin tissue applications.
• Dialysis concentrates Dialysis solutions and concentrates for renal therapy, manufactured using modernized production facilities as part of the company's 5 basic technological areas.
• Contract manufacturing services Full-service pharmaceutical contract manufacturing including substance procurement, development, validations, processing design/verification/control, packaging/labeling, laboratory testing, quality assurance, releasing, and warehousing. Specializes in single and multi-chamber PP flexible bags from 100ml to 5000ml for multinational pharmaceutical companies.

Quantifiable outcome

• Production capacity of up to 4000 units per hour on FFS machines

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Instituto Grifols (Grifols)coreStrategic or Co-development PartnerBlood derivatives partnership where IMUNA PHARM administers plasma collection in the Slovak Republic. Plasma is processed by Instituto Grifols in Spain and returned to the Slovak market in the form of medical substances. IMUNA PHARM is the only company in Slovakia offering blood derivatives from Slovak plasma.
• Bohemia Pharmaceuticals s. r. o.minorStrategic or Co-development PartnerPartnership for research on innovative therapeutic and technological procedures for combined vaccine production and establishment of seed lot system (project 2013-14549/39695:1-11, 2013-2016, subsidy 1,978,875 EUR).
• Virologický ústav SAV (Virology Institute of the Slovak Academy of Sciences)minorStrategic or Co-development PartnerPartnership for research on new final forms of viral vaccines with the goal of optimizing their stability and efficacy (project 3615/2010-11, 2010-2013, subsidy 1,950,000 EUR).
• Probiotech Consortium PartnersminorStrategic or Co-development PartnerCompetence Centre for Biomodulators and Nutritional Supplements (Probiotech) consortium including: Ústav fyziológie hospodárskych zvierat SAV, Neurobiologický ústav SAV, Parazitologický ústav SAV, Univerzita Pavla Jozefa Šafárika, Univerzita veterinárneho lekárstva a farmácie, Výskumný ústav mliekarenský a.s., and IMUNA PHARM (2011-2015, total project 6,963,744 EUR).

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Zentiva: Czech-headquartered generic pharmaceutical manufacturer with a comparable Central European footprint, offering generics, OTC products, and contract manufacturing. Similar mid-cap profile and geographic focus make it a directly comparable peer in generics, infusion solutions, and consumer health.
• STADA Arzneimittel AG: German-headquartered pharmaceutical company with generics, specialty pharma, and consumer health portfolios across Europe. Comparable mid-market scale and product breadth, particularly in OTC and sterile pharmaceutical formats.
• HUMAN BioPlazma: Slovak plasma products manufacturer focused on plasma collection and processing for therapeutic use. Direct regional peer with overlapping capabilities in blood-derived pharmaceutical products serving the Slovak and broader Central European markets.
• KRKA: Slovenian pharmaceutical company producing generic drugs, non-prescription products, and animal health products. Comparable in scale, Eastern European geographic focus, and vertically integrated pharmaceutical manufacturing model.

Broad incumbents

• B. Braun: German global medical and pharmaceutical device company with significant infusion solutions and sterile medical packaging business directly overlapping with IMUNA's FFS-based infusion and dialysis solution manufacturing.
• Octapharma: Swiss privately-held pharmaceutical company specializing in plasma-derived therapeutic products including coagulation factors and immunoglobulins. Comparable in plasma products niche and private ownership structure.
• Fresenius Kabi: German healthcare company with significant infusion solutions, clinical nutrition, and sterile injectable pharmaceutical manufacturing operations. Directly comparable in infusion bag and sterile solution manufacturing.
• Kedrion Biopharma: Italian biopharmaceutical company focused on plasma-derived therapies and rare disease treatments. Comparable in plasma fractionation, blood derivatives, and European contract manufacturing of plasma products.
• Sandoz: Global generic and biosimilar pharmaceutical manufacturer (Novartis division) with broad sterile injectable and pharmaceutical manufacturing capabilities. Comparable in sterile pharmaceutical preparation manufacturing and contract manufacturing services.

Emerging players

• Biotest AG: German specialty pharmaceutical company focused on plasma proteins and biotherapeutic products for hematology, immunology, and intensive care. Comparable plasma-derived product portfolio with narrower geographic footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/imuna-pharm-a-s-

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMUNA PHARM